骨保护素对激素性股骨头坏死骨密度及髋关节Harris评分的影响  

Effect on Harris hip score of osteoprotegerin for bone mineral density in patients with hormone osteonecrosis

作　　者：康亦锋[1] 

机构地区：[1]湖南省人民医院骨科,湖南长沙410002

出　　处：《局解手术学杂志》2015年第6期657-659,共3页Journal of Regional Anatomy and Operative Surgery

摘　　要：目的探讨骨保护素对激素性股骨头坏死骨密度及髋关节Harris评分的影响。方法选取我院骨科收治的激素性股骨头坏死患者60例,随机分为2组。对照组30例,予降钙素常规治疗,2周为1个疗程,治疗2个疗程;实验组30例,在常规治疗的基础上加用骨保护素0.5 mg/kg,2周为1个疗程,治疗2个疗程。治疗结束后,比较治疗前后患者骨密度、疼痛指数及髋关节Harris评分。结果治疗后,2组局部骨密度和平均骨密度均有所增高,实验组局部骨密度(0.99±0.20)g/cm^2和平均骨密度(0.98±0.25)g/cm^2与对照组[(0.84±0.22)g/cm2、(0.81±0.23)g/cm2]比较明显改善,差异有统计学意义(P<0.05)。2组患者的疼痛指数评分均有所降低,与对照组疼痛指数评分(1.56±1.02)分比较,实验组疼痛指数评分(0.76±0.62)分明显改善,差异有统计学意义(P<0.05)。2组患者的疼痛指数等级有所降低,且实验组优于对照组,差异有统计学意义(P<0.05)。2组患者的Harris评分均有所提高,与对照组疼痛指数评分(83.15±14.63)分比较,实验组疼痛指数评分(92.10±12.23)分明显改善,差异有统计学意义(P<0.05)。2组患者Harris评分分级,疼痛指数等级均有所降低,且实验组优于对照组,差异有统计学意义(P<0.05)。结论骨保护素能够明显改善激素性股骨头坏死患者的临床指标,在临床上具有指导意义。Objective To explore the effect on Harris hip score of osteoprotegerin for bone mineral density in patients with hormone os- teonecrosis. Methods Sixty patietns with glucocorticoid-induced avascular necrosis admitted in our hospital were randomly divided into two groups ,30 cases in the control group received routine calcitonin treatment for a period of 4 weeks treatment, 30 cases in the experimental group treated by femoral head subperiosteal injection for bone protection （0.5 mg/kg） based on conventional treatment for a period of 4 weeks. Then the bone mineral density, pain index and Harris hip score of 2 groups before and after treatment were compared. Results The bone mineral density of 2 groups has increased after treatment, compared with control group [ （ 0.84 ± 0.22 ） g/cm2, （ 0.81 ±0.23 ） g/cm2 ] , the bone mineral density of experimental group increased obviously [ （0.99 ±0.20） g/cm2,0.98 ± 0.25 ） g/era2 ]. The pain index score of 2 groups has decreased, the pain index score of experimental group （0.76 ± 0.62） point was lower than that of control group （ 1.56 ±1.02） point. The pain index level of experiment group was more excellent than that of control group. The Harris score of experimental group （92.10 ±12.23） point was obviously higher than that of control group（ 83. 15 ± 14.63 ） point. The level of Harris score in experimental group was more excellent than that in control group. The difference was statistically significant （ P 〈 0.05 ）. Conclusion Osteoprotegerin can obviously improve the patient＇s clinical indicators,which has guiding significance for hormone osteonecrosis in clinic.

关 键 词：骨保护素 激素性股骨头坏死 骨密度 髋关节Harris评分 

分 类 号：R681.8[医药卫生—骨科学]